Serum Institute of India (SII) chief Adar Poonawalla on Saturday said he is hopeful of launching a new COVID-19 vaccine under the brand name Covovax by June. The Institute had earlier applied for clearance to conduct a trial for the vaccine in India.
Covovax is being developed by American company Novavax.
The vaccine was found to be 89.3% effective in a U.K. trial and was nearly as effective in protecting against the U.K. variant. Mr. Poonawalla has said the SII’s partnership with Novavax, a vaccine undergoing trials for effectiveness against the novel coronavirus, has published “excellent efficacy results”.
Taking to Twitter, Mr. Poonawalla wrote, “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!”
Apart from Covovax, four more vaccines are in the pipeline for India.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
